免疫调节纳米凝纳米系统用于患者有利的癌症治疗
Sung Hoon Kim1, Rafael T Han2,3,4, Hyung-Seop Han1
1Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Bioactive materials
|September 27, 2024
概括
一个新的纳米凝系统通过单次注射产生瘤抗原和辅助剂,增强癌症免疫疗法并通过向瘤免疫微环境 (TIME) 来减少副作用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 生物材料是一种生物材料.
背景情况:
- 目前的癌症免疫疗法由于抑制瘤免疫微环境 (TIME) 的效果有限.
- 现有的免疫疗法诱导方法通常需要多次注射,并且缺乏对免疫反应的精确控制,从而冒着诸如细胞因子风暴等不良影响的风险.
- 有需要的患者方便的策略,可以调节的时间和增强抗瘤免疫力.
研究的目的:
- 开发和评估以患者为中心的纳米凝纳米系统,用于持续的抗原生成和辅助剂释放.
- 研究该系统能够引起局部抗瘤免疫力,并通过单次注射增强现有的免疫疗法的能力.
- 评估系统和记忆T细胞反应的诱导,同时最大限度地减少非目标副作用.
主要方法:
- 一个纳米凝纳米系统的设计,用于针对性地将药物输送到癌细胞和抗原/辅助剂到免疫细胞.
- 通过单次注射给药系统,以在瘤部位持续释放治疗剂.
- 评估局部抗瘤免疫力,治疗增强免疫检查点阻塞,并诱导全身/记忆T细胞反应.
主要成果:
- 纳米凝纳米系统证明了持续生成与瘤相关的抗原和辅助剂释放.
- 该系统的一次注射成功诱导了局部抗瘤免疫力.
- 该系统增强了免疫检查点阻塞的有效性,并促进了全身,记忆T细胞的反应,并减少了副作用.
结论:
- 开发的以患者为中心的纳米凝纳米系统为癌症免疫治疗提供了一个有前途的单次注射策略.
- 这种方法有效调节瘤免疫微环境,改善治疗结果,并最大限度地减少全身毒性.
- 该系统有可能提高癌症免疫治疗中的患者便利性和治疗效率.
相关概念视频
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


